Table 4 Pharmacological treatment of both men and women with angina for the year ending March 2002.
| Treatment | Age group (years) | p Value for trend for age groups | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| <45 | 45–54 | 55–64 | 65–74 | 75–84 | ⩾85 | <75 | ⩾75 | All ages | ||
| Number | 206 | 930 | 2 278 | 3 167 | 2 355 | 572 | 6581 | 2 927 | 9508 | |
| β blocker | 95 (46.1%) | 505 (54.3%) | 1 235 (54.2%) | 1 585 (50.0%) | 1 035 (43.9%) | 195 (34.1%) | 3 420 (52.0%) | 1 230 (42.0%) | 4650 (48.9%) | <0.001 |
| CCB | 46 (22.3%) | 342 (36.8%) | 1 010 (44.3%) | 1 385 (43.7%) | 1 050 (44.6%) | 207 (36.2%) | 2 783 (42.3%) | 1 257 (42.9%) | 4040 (42.5%) | <0.001 |
| Nitrates | 90 (43.7%) | 464 (49.9%) | 1 219 (53.5%) | 1 751 (55.3%) | 1 441 (61.2%) | 338 (59.1%) | 3 524 (53.5%) | 1 779 (60.8%) | 5303 (55.8%) | <0.001 |
| Nicorandil | 1 (0.5%) | 6 (0.6%) | 33 (1.4%) | 28 (0.9%) | 43 (1.8%) | 11 (1.9%) | 68 (1.0%) | 54 (1.8%) | 122 (1.3%) | 0.002 |
| ACEI | 42 (20.4%) | 246 (26.5%) | 686 (30.1%) | 1 016 (32.1%) | 743 (31.5%) | 137 (24.0%) | 1 990 (30.2%) | 880 (30.1%) | 2870 (30.2%) | <0.001 |
| ARB | 3 (1.5%) | 24 (2.6%) | 75 (3.3%) | 168 (5.3%) | 96 (4.1%) | 18 (3.1%) | 270 (4.1%) | 114 (3.9%) | 384 (4.0%) | <0.001 |
| ACEI/ARB | 43 (20.9%) | 264 (28.4%) | 735 (32.3%) | 1 138 (35.9%) | 815 (34.6%) | 150 (26.2%) | 2 180 (33.1%) | 965 (33.0%) | 3145 (33.1%) | <0.001 |
| Statins | 79 (38.3%) | 523 (56.2%) | 1 353 (59.4%) | 1 864 (58.9%) | 848 (36.0%) | 53 (9.3%) | 3 819 (58.0%) | 901 (30.8%) | 4720 (49.6%) | <0.001 |
| Aspirin | 104 (50.5%) | 546 (58.7%) | 1 592 (69.9%) | 24 05 (75.9%) | 1 698 (72.1%) | 375 (65.6%) | 4 647 (70.6%) | 2 073 (70.8%) | 6720 (70.7%) | <0.001 |
| Clopidogrel | 7 (3.4%) | 40 (4.3%) | 88 (3.9%) | 140 (4.4%) | 89 (3.8%) | 15 (2.6%) | 275 (4.2%) | 1 04 (3.65%) | 379 (4.0%) | 0.332 |
| Antiplatelets* | 105 (51.0%) | 567 (61.0%) | 1 636 (71.8%) | 2 483 (78.4%) | 1 149 (74.3%) | 383 (67.0%) | 4 791 (72.8%) | 2 132 (72.8%) | 6923 (72.8%) | <0.001 |
| Warfarin | 3 1.5%) | 25 (2.7%) | 93 (4.1%) | 176 (5.6%) | 205 (8.7%) | 25 (4.4%) | 297 (4.5%) | 230 (7.9%) | 527 (5.5%) | <0.001 |
| Optimal treatment† | 25 (12.1%) | 166 (17.8%) | 450 (19.8%) | 621 (19.6%) | 325 (13.8%) | 23 (4.0%) | 1 262 (19.2%) | 348 (11.9%) | 1610 (16.9%) | <0.001 |
*Aspirin or clopidogrel; †antiplatelet agent + statin + angiotensin converting enzyme inhibitor (ACEI).
ARB, angiotensin receptor blocker; CCB, calcium channel blocker.